Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 2Phase 1 1

Status

Terminated 2Completed 1

Sponsor Class

OTHER 2NETWORK 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 10Myeloid 8Dermatologic 8CNS 4Genitourinary 3Gastrointestinal 2Lymphoid 1Head & Neck 1Endocrine 1

Conditions

Kidney Neoplasms 3Carcinoma, Renal Cell 3

Interventions

Docetaxel 191Gemcitabine 148Prednisone 142pembrolizumab 125enzalutamide 119Abiraterone Acetate 108Nivolumab 107Cisplatin 103Magnetic Resonance Spectroscopy 100Radiotherapy 95Sunitinib 94Leuprolide 91Carboplatin 82Specimen Handling 71Androgen Antagonists 63bicalutamide 60Radiosurgery 60Paclitaxel 59Goserelin 59Ipilimumab 57Bevacizumab 57apalutamide 53Sorafenib 53acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 51Everolimus 49cabozantinib 48abiraterone 46atezolizumab 45cabazitaxel 43durvalumab 42

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × peginterferon alfa-2b × Genitourinary × Clear all
NCT00090870 2018-07-12

PEG-Interferon Alfa-2b, Sargramostim, and Thalidomide in Treating Patients With Metastatic Kidney Cancer

Medical University of South Carolina

Phase 2 Terminated
10 enrolled 4 charts
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

NCT00467077 2017-03-17

Gefitinib and PEG-Interferon Alfa-2b in Treating Patients With Unresectable or Metastatic Kidney Cancer

California Cancer Consortium

Phase 2 Terminated
21 enrolled 8 charts
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

NCT00045279 2013-06-05

PEG-Interferon Alfa-2b in Treating Patients With Metastatic Kidney Cancer

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡